Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They got paid I assure u.
Yippie… That should lower the price by another 20%.
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.” - IPIX CEO
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
Source: Management’s Plan of Operation, page 27, most recent 10Q filing - link below for context:
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Oh does it ever!
Doesn’t look like anyone is buying it.
.009’s are on deck.
If Brilacidin was worth more than the CEO’s paycheck, it would have been picked up by Pharma long ago.
Below you’ll find a link to the filings and most recent 10Q. Search for key words, like nasal and funding.
You’ll find ZERO results for Nasal.
You’ll also find 1.) the company doesn’t have financial resources to advance Brilacidin into clinical trials and 2.) the company plans to AVOID such investments of time and financial resources.
In the CEO’s own words from Management’s Plan of Operation, page 27, most recent 10Q filing - link below for context:
“Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully.” - IPIX CEO
“In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.“ - IPIX CEO
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
Isn’t that how they pay their taxes?
$940,000/yr in salary/bonuses. Not to mention stock/option awards! Dilution to sustain these type compensations near a penny will keep driving the stock price lower and lower.
2022 recap - the CEO received compensation of approx. $11,000/week from the company and based on the filings didn’t do jack shit except give away $4M to a foreign private company for a product that may or may not ever come to fruition. And then there’s Jane….
Looks like IPIX will be under a penny in 2023.
I can’t believe it!
Somewhat. Thank you.
As predicted. There will be another zero in there soon enough.
“I don't think that IPIX is a shell so a merger would be just a merger.” Perhaps.
Perhaps a reverse merger.
Yes. A dreaded nightmare for most.
IPIX - an investment of hopes and prayers.
It’s really a sad story.
Questions for the board.
Is IPIX a shell company at this point in time in your opinion?
Is there a scenario where merging IPIX and the laser company would be beneficial to shareholders?
Today’s update reinforces what we already know - a whole lot more of nothing is planned by the company that will benefit shareholders.
Published June 10, 2016. Shareholder value was 75 times greater at that time. Happenings since then…. Look no further…
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Follow the money.
Look no further.
No human trials. Dumping the little capital we have on lasers?? One doesn’t have to be a rocket scientist to see the writing on the wall here.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793222008313/ipix_10q.htm
2. Liquidity, Going Concern and Management’s Plan
Our financial statements were prepared assuming we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. For the three months ended September 30, 2022, the Company had a net loss of $1.4 million and negative cash flow from operations of $0.8 million. As of September 30, 2022, the Company has negative working capital of $2.0 million. As of September 30, 2022, the Company’s cash amounted to $3.0 million and current liabilities amounted to $5.1 million. The Company has expended substantial funds on its clinical trials and expects to continue our spending on research and development expenditures. We expect to incur further losses in the development of our business and have been dependent on funding operations from inception. These conditions raise substantial doubt about our ability to continue as a going concern. Management’s plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
These factors raise a substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.
It’s more likely to be something it’s not. How promising. Out of cash. Out of time. Lasers heh.
Stock price/volume, market cap and filings show IPIX and its drugs are forever dead.
It’s very evident.
There’s certainly a shitton of bagholders with not many options at this price.
Yup. Their foot in the door to swindle $4M from IPIX shareholders.
LOL. Oh man. Back to the charts I guess….
A turd is a turd.
Here’s what’s next! We’ll see significant downward price movement near term on the order of 25% settling into range bound trading between 1.5/1.75 and 1.75/2 pennies as the chart sets up for the next leg down. .02 will prove to be strong resistance.
Single penny and change is printing.